Recent Progress in Mind-Body Therapies in Cancer Care.
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
accepted:
18
11
2022
medline:
5
4
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Mind-body therapies (MBTs) are integrative medicine modalities that continue to grow in popularity among people with cancer. MBTs are used to enhance well-being and most commonly include relaxation and imagery, hypnosis, yoga, meditation, Tai Chi and Qigong, and creative therapies. Biofield and psychedelic-assisted therapies are also gaining momentum as MBTs. Herein, recent literature was narratively reviewed to summarize the effectiveness of these MBTs within the context of cancer care. There is growing evidence for the effectiveness of MBTs for addressing a myriad of physical (e.g., pain) and psychosocial (e.g., depression, fatigue) symptoms and biomarkers of stress and immune function in people with cancer. Psychedelic-assisted therapies have robust, sustained effects on symptoms of depression, anxiety, and distress in small clinical trials to date. However, across modalities, MBT studies continue to struggle with methodological issues such as intervention standardization, facilitator training, small sample sizes, and short follow-up. Accumulating evidence supports the use of MBTs for people with cancer. Future research should work to address methodological issues and focus on creating knowledge translation tools; these can be leveraged to better educate health care providers and patients regarding evidence-based MBT options to support patients in making informed decisions about their health.
Identifiants
pubmed: 36753025
doi: 10.1007/s11912-023-01373-w
pii: 10.1007/s11912-023-01373-w
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-307Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.